Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE005 (FRA) (Dr. Muller)
· consented 2022-10-28
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 54); relationship: N
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 91); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-04-05 (study day 145); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 273); relationship: N
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-09 (study day 302); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.